On 03 February 2026, Shandong Weigao Group Medical Polymer Company Limited (01066) repurchased 140,000 H shares on the Hong Kong Stock Exchange at prices ranging between HKD 5.00 and HKD 5.07, with an aggregate payment of HKD 706,600. These purchased shares were retained as treasury shares, increasing the total number of treasury shares to 40,486,400.

Following the repurchase, the number of issued shares (excluding treasury shares) changed to 4,481,845,924, while the total number of issued shares remained at 4,522,332,324. The repurchase was carried out under a mandate granted on 27 May 2025, which authorized up to 451,560,392 shares to be repurchased. According to the announcement, 33,838,000 shares have been repurchased to date under this mandate, representing approximately 7.4936% of the company’s issued shares at the time of the resolution. A moratorium applies until 05 March 2026, during which no new share issuance or treasury share disposal is permitted without prior approval of the Hong Kong Stock Exchange.